Riyadh - Mubasher: Jamjoom Pharmaceuticals Factory Company (Jamjoom Pharma) recorded 30.10% year-on-year (YoY) higher net profits attributable to the shareholders at SAR 463.80 million in 2025, compared with SAR 356.50 million.
The earnings per share (EPS) grew to SAR 6.63 last year from SAR 5.09 in 2024, according to the annual financial statements.
Jamjoom Pharma posted 13.81% YoY higher revenues at SAR 1.50 billion as of 31 December 2025, compared to SAR 1.31 billion.
Dividends for H2-25
The board members approved cash dividends totaling SAR 140 million, equivalent to 20% of its SAR 700 million capital, for the second half (H2) of 2025.
Meanwhile, the Saudi company will pay out a dividend of SAR 2 per share for 70 million eligible shares.
The eligibility and distribution dates will be 1 and 15 March 2026, respectively.
During the first nine months (9M) of 2025, Jamjoom Pharma generated net profits after tax worth SAR 395.73 million, up 29.78% YoY from SAR 304.92 million.
